[Promoting responsible self-medication in the context of Parkinson's disease: Development of a practical guide for drug-drug interactions and assessment by patients and community pharmacy professionals].
Sensibilisation à l’automédication responsable au cours de la maladie de Parkinson : réalisation de fiche sur les interactions médicamenteuses et évaluation par les patients et les professionnels de l’officine.
Automédication
Drug-drug interaction
Interaction médicamenteuse
Maladie de Parkinson
Parkinson's disease
Self-medication
Journal
Annales pharmaceutiques francaises
ISSN: 0003-4509
Titre abrégé: Ann Pharm Fr
Pays: France
ID NLM: 2985176R
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
16
09
2021
revised:
07
02
2022
accepted:
31
03
2022
pubmed:
28
4
2022
medline:
25
10
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Parkinson disease is a neurodegenerative disorder characterized by motor and non-motor symptoms. Symptomatic treatment is based on dopaminergic medications. In case of self-medication practices, there may be drug-drug interactions between over-the-counter medication and dopaminergic medications. Thus, the aim of our work was to develop a practical guide summarizing drug-drug interactions and assess it by patients and community pharmacy professionals. We performed a systematic analysis of drug-drug interactions between OTC medications available in France and antiparkinsonians (ATC Class N04) using Theriaque® and Drugs® databases, and summarized the results in a practical guide. We assessed patients' satisfaction by a questionnaire administered to hospitalized patients in a French expert center for Parkinson's disease. We estimated the impact of the guide on community pharmacy professionals through a survey online, by satisfaction, knowledge acquisition and estimated awareness in professional context. We identified 16 OTC medication, related to seven symptoms, interacting with antiparkinsonians. We obtained 67 responses from patients, expressing high satisfaction. We obtained 101 responses from professionals, reporting high satisfaction, knowledge acquisition and increased awareness in professional context. Our results highlight the relevance of the guide and suggest that we may increase its dissemination to patients and community pharmacies.
Identifiants
pubmed: 35476969
pii: S0003-4509(22)00036-0
doi: 10.1016/j.pharma.2022.03.005
pii:
doi:
Substances chimiques
Nonprescription Drugs
0
Antiparkinson Agents
0
Types de publication
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
981-987Informations de copyright
Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.